Категории

IAS 2017 Rapporteur and Closing Session

Опубликовано: 17 Июль 2026
на канале: IAS Conference on HIV Science
870
7

WEPL02: Rapporteur and Closing Session. Anton Pozniak. Presented at the 9th IAS Conference on HIV Science (IAS 2017). www.ias2017.org

play_arrow
876
2

00:00:00

Тачовузи кудаки ноболиг ва дузди

Тачовузи кудаки ноболиг ва дузди
play_arrow
12,888
76

COMO HACER FOTOS LIVE EN IPHONE 🟢

COMO HACER FOTOS LIVE EN IPHONE 🟢
play_arrow
1,619
54

Lil Peep - Lil Jeep (Natural Vocals)

Lil Peep - Lil Jeep (Natural Vocals)
play_arrow
45,233
338

How to Reset Your CASIO Scientific Calculator Back to Factory Settings

How to Reset Your CASIO Scientific Calculator Back to Factory Settings
play_arrow
73,733
2.6 тыс

!בניתי עמדת גיימינג 8קיי ב40 אלף שח

!בניתי עמדת גיימינג 8קיי ב40 אלף שח
play_arrow
945
4

20 Pack Hi-Tech Callouts Stock Motion Graphics

20 Pack Hi-Tech Callouts Stock Motion Graphics
play_arrow
89
0

00:00:00

Духтаре Ки Наздик буд Ба У Тачовуз шавад Ки .....

Духтаре Ки Наздик буд Ба У Тачовуз шавад Ки .....
play_arrow
66
0

טיפול ביובש בעיניים - אופטיק 135

טיפול ביובש בעיניים - אופטיק 135
Похожие видео
play_arrow
The Mexico City story: Proud hosts of the 10th IAS Conference on HIV Science (IAS 2019)

The Mexico City story: Proud hosts of the 10th IAS Conference on HIV Science (IAS 2019)
play_arrow
On-demand Oral TDF/FTC for PrEP: Is It an Option?

On-demand Oral TDF/FTC for PrEP: Is It an Option?
play_arrow
Challenges and Opportunities in HIV Science

Challenges and Opportunities in HIV Science
play_arrow
Welcome to Paris - IAS 2017

Welcome to Paris - IAS 2017
play_arrow
TUAB0102 - Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir ...

TUAB0102 - Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir ...
play_arrow
TUAB0101 - Atazanavir/ritonavir 200/100 mg is non-inferior to atazanavir/ritonavir 300/100 mg ...

TUAB0101 - Atazanavir/ritonavir 200/100 mg is non-inferior to atazanavir/ritonavir 300/100 mg ...
play_arrow
Primary HIV Infection and Early Treatment

Primary HIV Infection and Early Treatment
play_arrow
Broadly Neutralizing Antibodies against HIV

Broadly Neutralizing Antibodies against HIV
play_arrow
Antiretroviral Therapy - ART: Season One

Antiretroviral Therapy - ART: Season One
play_arrow
Plenary Session

Plenary Session
play_arrow
IAS 2017 Rapporteur and Closing Session

IAS 2017 Rapporteur and Closing Session
play_arrow
Antiretroviral Therapy - ART: Season Two

Antiretroviral Therapy - ART: Season Two